Combination therapy may be required for multidrug-resistant (MDR) Pseudomonas
aeruginosa. The aim of this study was to systematically investigate bacterial killing and …

Objectives Colistin is an 'old'drug, which is being increasingly utilized due to limited
therapeutic options. However, resistance emergence during monotherapy is concerning …

The use of combination antibiotic therapy may be beneficial against rapidly emerging
resistance in Pseudomonas aeruginosa. The aim of this study was to systematically …

Objectives Colistin combination therapy may be required to treat biofilm-associated
infections. We evaluated bacterial killing and emergence of colistin resistance with colistin …

Despite the marketing of a series of new antibiotics for antibiotic-resistant gram-positive
bacteria, no new agents for multiple-antibiotic-resistant gram-negative infections will be …

Colistin plays a key role in treatment of serious infections by Pseudomonas aeruginosa. The
aims of this study were to (i) identify the pharmacokinetic/pharmacodynamic (PK/PD) index …

Objectives Combination therapy can be a strategy to ensure effective bacterial killing when
treating Pseudomonas aeruginosa, a Gram-negative bacterium with high potential for …

Multidrug-resistant (MDR) Klebsiella pneumoniae may require combination therapy. We
systematically investigated bacterial killing with colistin and doripenem mono-and …

Objectives An optimized dosing regimen of the prodrug of colistin, colistin
methanesulphonate (CMS), against resistant Pseudomonas aeruginosa is needed to ensure …

Objectives The optimal dosing regimen for colistin methanesulphonate (CMS) against
Pseudomonas aeruginosa is unknown. CMS is converted in vivo to its active form, colistin …